Roche Collaborates with Icagen for the Development of Drug Candidates for Neurological Disorders

Shots:

• Icagen to receive upfront, up to $274M milestones and royalties on sales from Roche and is responsible for all preclinical activities
• Roche to fund the program and will perform further development and commercialization activities
• The focus of the collaboration is to develop pre-clinical stage ion channel modulators using Icagen’s drug discovery platform, for targeting ion channel in neurons

Click here to read full press release/ article | Ref: Icagen | Image: Twitter